Evaluating eating behavior treatments by FDA standards by A. Janet Tomiyama et al.
“fpsyg-04-01009” — 2013/12/30 — 16:56 — page 1 — #1
PERSPECTIVE ARTICLE
published: 03 January 2014
doi: 10.3389/fpsyg.2013.01009
Evaluating eating behavior treatments by FDA standards
A. JanetTomiyama1*, Britt Ahlstrom1,2 andTraci Mann2
1 Department of Psychology, University of California, Los Angeles, Los Angeles, CA, USA
2 Department of Psychology, University of Minnesota, Minneapolis, MN, USA
Edited by:
Esther Katharina Papies, Utrecht
University, Netherlands
Reviewed by:
Jacob Burmeister, Bowling Green
State University, USA
Michael R. Lowe, Drexel University,
USA
Hubert Preissl, University of Tübingen,
Germany
*Correspondence:
A. Janet Tomiyama, Department of
Psychology, University of California,
Los Angeles, 1285 Franz Hall, 502
Portola Plaza, Los Angeles, CA
90095-1563, USA
e-mail: tomiyama@psych.ucla.edu
Behavioral treatments for obesity are not evaluated by the same criteria as pharmaceutical
drugs, even though treatments such as low-calorie dieting are widely prescribed, require
patients’ time and investment, and may have risks.The Food and DrugAdministration (FDA)
has a procedure for evaluating drugs, in which drugmakers must answer the following
questions: (1) Is the treatment safe? (2) How dangerous is the condition the intervention
is treating? (3) Is the treatment effective? (4) Is the treatment safe and effective for
large numbers of people? We argue that using this framework to evaluate behavioral
interventions could help identify unanswered research questions on their efﬁcacy and
effectiveness, and we use the example of low-calorie dieting to illustrate how FDA criteria
might be applied in the context of behavioral medicine.
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INTRODUCTION
Obesity rates in America have more than doubled in the last
30 years, and currently one third of adults are considered obese,
and another third are considered overweight (Flegal et al., 2012).
Both the increase in obesity levels and the prevalence of obesity
are of great concern to our government, medical community,
and the public, and signiﬁcant efforts to prevent and treat obe-
sity are being made. The National Institutes of Health spent
$830 million on obesity research in ﬁscal year 2011. Unlike many
diseases, obesity is notable in that there is no gold-standard phar-
macological intervention. Most treatment approaches to obesity
involve some formof behavior change, andmost involve restrictive
dieting.
Behavioral interventions, however, are not evaluated accord-
ing to the same criteria as pharmaceutical drugs. In this article,
we argue that examining behavioral interventions using the cri-
teria of the Food and Drug Administration (FDA) is a useful
exercise for identifying unanswered research questions on the efﬁ-
cacy and effectiveness of behavioral treatments. We use dieting,
or the restriction of caloric intake for the purpose of weight loss,
as our exemplar, and outline how researchers might beneﬁt from
applying the standard criteria used for evaluating drugs.
The goal of governmental agencies like the FDA is to protect
public health and promote the use of safer and more effective
treatments. Although behavioral interventions are not regulated
by the FDA, behavior can affect health profoundly. McGinnis and
Foege (1993) estimated that 40% of US deaths were preventable
through changing behavior, and this appeared to still be true a
decade later (Mokdad et al., 2004). Behavioral treatments can even
outperform pharmaceutical treatments, as was the case with the
Diabetes Prevention Program (Knowler et al., 2009).
We suggest that several factors have conspired to create a sit-
uation where behavioral treatments are not considered worthy of
regulatory oversight. First, most behavioral interventions involve
commonplace behaviors. In the case of dieting, the behavior is
undertaken frequently to improve one’s appearance. Second, the
changes in health outcomes are often slow. Most dieting inter-
ventions lead to 1 pound per week of weight loss, whereas, for
example, a dose of epinephrine will immediately cure anaphy-
laxis. Third, behavioral interventions are not perceived to carry
the same level of risks as pharmaceutical treatments – they are
not ingested, and they are non-invasive. These reasons are cer-
tainly understandable, but are fallacious as arguments for why
behavioral treatments do not need to be evaluated as rigorously
as are pharmaceutical drugs. Commonplace behaviors can be
deadly (e.g., driving a car). Health outcomes that change slowly
can also be deadly (e.g., cancer). Behavioral interventions may
carry fewer risks than pharmaceutical treatments, but they are
likely not without any risks – risks that do not undergo regulatory
oversight before being recommended to patients. Accordingly, in
this article we demonstrate how one might evaluate behavioral
treatments using the Manual of Policies and Procedures (MAPP)
created by the FDA’s Center for Drug Evaluation and Research
(2010).
FDA FRAMEWORK
To obtain FDA approval, ﬁve questionsmust be addressed over the
course of four phases of trials. Phase 1 comprises two questions:
(1) Is the treatment safe? (2) How dangerous is the condition? The
latter question is necessary because the riskiness of treatments
must be balanced by the severity of the problems being treated.
The more severe the problem, the more we may be willing to use
treatments that have potentially harmful side effects. Treatments
that involve high risk would not be offered for a common cold, but
might be offered for a deadly type of cancer. In Phase 2, the FDA
asks: is the treatment effective? In Phase 3, the FDA asks: is the
treatment safe and effective for large numbers of people? Phase 4
is a post-approval phase that we will not discuss here.
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The most rigorous form of evaluation study is a randomized
controlled trial (RCT), and enough of these types of trials exist
in eating behavior interventions that we suggest only considering
RCTswhen applying FDAcriteria to them in the context of efﬁcacy.
When looking at evidence from clinical trials, the FDA considers
the type and sample size of those trials. Phase 1 clinical trials have
the smallest sample size and test for the safety of the treatment,
and determine whether the treatment has side effects. Phase 2
trials primarily use RCTs of a few 100 participants to test how
well the treatment works. Phase 3 trials tend to involve many
thousands of people and gather further information about the
populations in which the treatment is effective. They may also
compare the treatment’s efﬁcacy against the current gold-standard
treatment.
APPLYING FDA CRITERIA TO DIETING
In the following sections, we use dieting as a test case to
describe how we might apply the FDA criteria to eating behavior
interventions.
PHASE 1: SAFETY OF TREATMENT VERSUS DANGEROUSNESS OF
CONDITION
Is dieting safe?
Any drug, in order to be approved by the FDA, must be evaluated
for its safety. All the side effects of the drug must be reported so
that wemay ultimately assess whether the beneﬁts of the treatment
outweigh those risks. Examples of “side effects” in the dieting con-
text might be eating disorder pathology (Stice et al., 2011), binge
eating (Polivy and Herman, 2002; Wadden et al., 2004), malnutri-
tion (French and Jeffery, 1994), smoking, alcohol, and marijuana
use (Krahn et al., 2005; Crow et al., 2006; Seo and Jiang, 2009),
depression (Wadden et al., 2004), psychological distress (Isomaa
et al., 2010), lower self-esteem (Pesa, 1999; Ackard et al., 2002),
cognitive deﬁcits (McFarlane et al., 1999), weight cycling (Diaz
et al., 2005), and stress (Tomiyama et al., 2010).
In discussing side effects, several considerations should be
addressed. Were the side effects observed in studies with longi-
tudinal or cross-sectional designs, rather than designs that allow
for causal inference? Some judgment must be made as to how
to balance studies documenting the respective side effects coun-
tered by studies failing to observe them. The timeframe of studies
varies widely, and it is unclear whether studies that test for but
do not ﬁnd evidence of speciﬁc side effects have sufﬁciently long
follow-up periods to observe the risks of dieting. Alternately, and
particularly in the case of experimental laboratory studies that
allow for causal inference but take place within a timeframe of
hours to days, documented side effects may be short-lived and of
minimal concern.
How dangerous is the condition?
This question seems straightforward, and often is in the case of
pharmaceutical treatments. In the context of behavioral treat-
ments, however, this question becomes more complex, as there
are multiple “conditions” that behavioral treatments are meant to
affect. Even in the case of dieting treatments, where the condi-
tion that dieting is meant to treat is almost always overweight
and obesity, the answer to this question is unclear. Although
the American Medical Association recently voted to label obesity
as a disease, there is substantial evidence that being overweight
does not increase risk for mortality (Flegal et al., 2013) or disabil-
ity (Alley and Chang, 2007), and the mortality risks associated
with obesity appear to have decreased over time (Flegal et al.,
2005). Furthermore, the majority of obesity-related deaths occur
among individuals with a body mass index (BMI) 35 and above
(Flegal et al., 2013). The research clearly shows that overweight
is not consistently associated with disability or mortality and
that many overweight and obese individuals experience few, if
any, adverse health consequences due to their weight. In many
studies, obesity is in fact associated with better outcomes – a
phenomenon known as the “obesity paradox” (Clark et al., 2011).
These results may indicate that the true problem is with the cur-
rent system of using BMI categories to characterize excess weight
(Kuczmarski and Flegal, 2000). Nevertheless, if overweight and
obesity under current BMI categories and guidelines are the “con-
ditions” that the FDAmust balance against the risks of dieting, the
risks will need to be shown as extremely minimal at BMI ranges
below 35.
Other conditions that dieting interventions are meant to treat
include hypertension, hypercholesterolemia, or insulin resis-
tance. The evidence that these conditions are dangerous is much
more defensible (see Tomiyama et al., 2013 for a review). Some
individuals diet to improve their quality of life and reduce dis-
ability, rather than to reduce their risk of death or disease.
And indeed, Jia and Lubetkin (2010) reported that all classes of
obesity combined contributed to 0.05 quality-adjusted life years
lost; a number that has more than doubled since 1993. How-
ever, the FDA does not include quality-adjusted years of life
lost in their consideration for approval, and as we summarize
next, the criterion on which dieting interventions are currently
evaluated is, in the overwhelming majority of trials, weight
change.
PHASES 2 AND 3: EFFICACY
What does it mean for dieting to work?
What to measure. In order to assess whether dieting is an effec-
tive treatment for overweight and obesity, we must ﬁrst decide
on appropriate criteria upon which to judge it. The MAPP refers
to this criterion as the primary endpoint, and for dieting, this
endpoint is nearly always weight loss. Although we would argue
that improved health rather than weight loss should be the mea-
sure of effectiveness, we recognize that weight loss is the currently
accepted deﬁnition of success. We therefore summarize how FDA
Phase 2 criteria would be appliedwhen evaluating the effectiveness
of dieting in reducing weight.
The necessary amount of weight loss for a diet to be considered
effective is somewhat arbitrary, and it has changed dramatically
since researchers ﬁrst started routinely studied dieting. The orig-
inal standard for success required dieters to reach a “normal”
weight as deﬁned by the Metropolitan Life Insurance Company
(1942). For example, an average height woman (5′5′′) of medium
body frame was expected to weigh about 134 pounds (Metropoli-
tan Life Insurance Company, 1942), so a 200-pound woman
of average height would need to lose 66 pounds to be con-
sidered a successful dieter. This standard was rarely achieved
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(Stunkard and McLaren-Hume, 1959), and over the next 50 years
the standard changed from losing 20% of one’s starting weight,
to 10%, and to just 5% of one’s starting weight (Institute of
Medicine, 1995, p. 5). Now, an average height woman weigh-
ing 200 pounds needs to lose just 10 pounds to be considered
a successful dieter. The use of this criterion as the primary
endpoint would need to be justiﬁed to the FDA in terms of
its validity and whether it provides “a reasonable assessment
of clinical beneﬁt” (Center for Drug Evaluation and Research,
2010).
When to measure it. In addition to selecting an appropriate end-
point, researchers also need to decide when that endpoint should
be assessed. The current standard set by the Institute of Medicine
is that individuals need to maintain a 5% weight loss for a year.
The year, however, is counted as beginning when the diet begins,
rather than beginning when that target weight is reached. This
convention is likely used to make it easier to evaluate and compare
diets, because individuals reach target weights at different time-
points. Regardless, the 1 year weight loss maintenance standard is
not actually a measure of whether one maintained weight loss for
a full year, but rather whether an individual is at the target weight
1 year after beginning the diet. TheMAPP requires a discussion of
the “adequacy of duration” of the clinical trials, and it is not clear
if this maintenance period would be considered adequate.
The issue of when to judge the success of a treatment is par-
ticularly complex when it comes to dieting. Dieters tend to take
off weight quickly at ﬁrst, then more slowly, followed by weight
regain over several more years (Garner and Wooley, 1991). The
effectiveness of the diet will look quite different if it is measured
at the end of the early stage when weight has come off, or later, as
it is regained.
Pharmaceutical treatments differ onwhether they are evaluated
during active treatment or at some time point after treatment ends.
An antibiotic would not be considered effective if the bacteria
were only eradicated during the time individuals were taking the
medication, and then came back again after the treatment ended.
Similarly, chemotherapy for cancer would not be judged effective
if tumors reappeared immediately at the end of treatment. On
the other hand, medications such as anti-depressants and pain
medications are only expected to be effective while individuals are
taking them.
It can be argued that diets are only expected to “work” while
individuals are actively engaging in them. If so, then the short-
term effectiveness would be considered the appropriate measure.
Proponents of this viewpoint argue that diets would work if indi-
viduals would just stay on them, and the short-term effectiveness
is the onlymeasure takenwhile individuals are still restricting their
intake. It is not yet known, however, if diets stop leading to weight
loss because individuals stop restricting their eating, or if individ-
uals stop restricting their eating because the diets stopped leading
to weight loss (or a combination of these). There is evidence that
dieters’ weight loss tends to level off during diets even while they
adhere to the diet (Tataranni and Ravussin, 2004), and that indi-
vidualswho successfully loseweight at a certain calorie level cannot
necessarilymaintain the newweight at that calorie level (Leibel and
Hirsch, 1984). If this is the case, then dieters should be informed
that they can only expect their diet to work for a somewhat brief
length of time. This is not a unique circumstance. For exam-
ple, extended use of medications such as alprazolam (Xanax) and
diazepam (Valium) can result inmedication tolerance (i.e., requir-
ing higher doses to achieve the same effect; Ellinwood et al., 1985),
and these anxiety medications are usually explicitly recommended
for short-term use. Another consideration is whether the use of
dieting treatment might make subsequent dieting treatments less
effective (Tataranni and Ravussin, 2004), just as cochlear implants
can render other treatments for hearing loss impossible (Lenarz
et al., 2013).
In terms of evaluating the effectiveness of diets, we are propo-
nents of the viewpoint that one cannot consider a diet successful
if individuals rapidly regain the weight they lost. According to this
viewpoint, the longer-term effectiveness is the appropriate mea-
sure. Obesity-related illnesses tend to be chronic diseases, such
as cardiovascular disease and diabetes, and to be successful, we
believe their treatments must lead to long-term beneﬁts.
Study design. In addition to describing the outcomes of the clinical
trials, the MAPP also requires a discussion of aspects of study
design that might limit the conclusions that can be drawn. One
area of focus is whether the validity of the study is threatened
by “subject disposition,” which includes both the rate of subject
exclusion from entry into the study and the rate of drop-outs.
Generalizability can be threatened when the exclusion criteria
for a study are so extensive that the sample is not representative
of typical users of that drug. In dieting studies, participants can
be excluded if their BMI is above a certain cut-off, they have a
present or past diagnosis of heart disease, angina, or other physi-
cal or psychological illnesses, or if their levels of certain macro-or
micro-nutrients (e.g., glucose, sodium) are too high (reviewed in
Tomiyama et al., 2013). These exclusions limit the generalizability
of the ﬁndings to just healthier dieters. Of more concern in terms
of generalizability, several studies exclude subjects that researchers
felt would not be able to adhere to the study requirements. These
multiple enrollment steps, called “run-in periods,” are often rec-
ommended in clinical trials and are intentionally stringent in order
to isolate a participant pool that will remain in the study until the
end (Friedman et al., 2010). This may result in samples of par-
ticipants who are more motivated and more successful at altering
their behavior than the average dieter. In one study, for example,
18.8% of the potential participants were excluded before the study
began for failing to control their diabetes with their diet for the
previous 6 weeks (Hanefeld et al., 1991).
Generalizability can also be threatened due to study attrition
(for a more detailed analysis of this problem, see Mann et al.,
2007). Many reasons for loss to follow-up are seemingly ran-
dom (e.g., the subject moves and can no longer be located by the
researchers). Others could be problematic (e.g., excluding subjects
from analyses because of serious illness or death). To the extent
that these drop-outs occur in differing proportions among the diet
and control conditions, internal validity may also be threatened.
Phase 3: the issue of adherence
A starting point to determine the patient populations for whom
dieting should be approved is examining the exclusion criteria
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for the original trials. Adherence to dieting is the most consistent
predictor of weight loss and changes in health outcomes (Pagoto
and Appelhans, 2013), and as noted above, non-adherent indi-
viduals are often excluded from trials. Despite the importance
of adherence, dieting interventions are not evaluated based on
whether participants are able to adhere to the regimen. Adher-
ence is often raised as the reason that a given trial succeeded
or failed, but that is a separate issue from using adherence as a
criterion upon which to judge dieting. The FDA addresses the
issue of adherence in section 208.1 of its code of regulations, and
states that special labeling should be used in cases when “patient
adherence to directions for use is crucial to the drug’s effective-
ness.” Under an FDA framework, dieting might be prescribed
along with label information about the importance of adher-
ence for the treatment’s effectiveness, including information that
even with 100% adherence, weight loss may plateau, as noted
above.
DISCUSSION
In this Perspective article, we considered whether viewing behav-
ioral interventions through the lens of FDA regulations is worth-
while. Using the FDA’s framework illuminated areas for future
research that may not have otherwise been considered. For exam-
ple, in evaluating dieting, current researchers do not consider the
intervention balanced against the severity of the condition it is
designed to treat. Dieting occupies a signiﬁcant portion of an
individual’s resources, and it may also prevent individuals from
attempting other forms of treatment. This analysis has also uncov-
ered thatmore research is needed on efﬁcacy in relation towhether
weight is lost but then regained; the length of treatment that is
required for a given level of efﬁcacy; how consistently and with
what level of adherence the dieting treatment must be “applied”
to reach efﬁcacy; and whether adherence to the treatment is a
realistic expectation. A ﬁnal strength of applying FDA criteria to
dieting is that it can serve to refocus the goals of dieting trials
squarely on improving health rather than reducing weight. Incor-
porating this framework into traditional methods of evaluation
may lead to new insights in the search for effective behavioral
treatments.
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